Skip to main content
Curocell Inc. logo

Curocell Inc. — Investor Relations & Filings

Ticker · 372320 ISIN · KR7372320002 KO Manufacturing
Open in API
Filings indexed 109 across all filing types
Latest filing 2024-03-19 Audit Report / Informat…
Country KR South Korea
Listing KO 372320

About Curocell Inc.

https://curocellbtx.com/

Curocell Inc. is a clinical-stage biotechnology company specializing in the development of Chimeric Antigen Receptor T-cell (CAR-T) therapies. The company focuses on engineering a patient's own immune cells to recognize and eliminate cancer, primarily targeting blood cancers. Curocell's proprietary OVIS™ technology is an immune checkpoint receptor platform designed to enhance the efficacy of CAR-T treatments by overcoming the immunosuppressive tumor microenvironment. The company has advanced its lead candidate, anbalcabtagene autoleucel (Limkato), through Phase 2 clinical trials and operates a state-of-the-art GMP facility for the production of its advanced cell therapies.

Recent filings

Filing Released Lang Actions
감사보고서제출
Audit Report / Information Classification · 1% confidence The document is a regulatory filing from the Korean Exchange (KRX) system titled 'Audit Report Submission' (감사보고서 제출). It provides a summary of the audit opinion, key financial data, and capital impairment status for the fiscal year. While it contains financial data, it is a standardized regulatory disclosure form used to announce the completion and submission of the audit report to the exchange, rather than the full audit report document itself. Therefore, it is classified as a Regulatory Filing (RNS). FY 2023
2024-03-19 Korean
사업보고서 (2023.12)
Audit Report / Information Classification · 1% confidence The document is a formal 'Audit Report' (감사보고서) for the company 'Curocell' (주식회사 큐로셀) for the fiscal year 2023. It includes the independent auditor's report, financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes to the financial statements. It is not an Annual Report (10-K) as it lacks the comprehensive business overview, management discussion, and other non-financial sections typical of a full 10-K. It is a standalone audit report and financial statement package. FY 2023
2024-03-19 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 1% confidence The document is a 'Report on Large Shareholding' (주식등의 대량보유상황보고서), which is a standard regulatory filing in South Korea (often referred to as a 5% report). It details changes in share ownership by InterVest Co., Ltd. in the company Curocell. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema, as it tracks significant ownership thresholds and changes therein.
2024-03-14 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and special related parties (insiders). This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2024-03-13 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share transactions (specifically '장내매수' or open market purchase) by an executive (Kang Hyuk) of the company Curocell. This type of filing is a standard disclosure for insider trading/director dealings in the Korean market, which corresponds to the 'Director's Dealing' category.
2024-03-13 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 1% confidence The document is a regulatory filing from a Korean company (큐로셀) regarding a significant change in financial structure (a 30% or greater change in revenue or profit/loss). This is a standard regulatory disclosure requirement in the Korean market (DART system) for material financial events. Since it provides specific financial figures and reasons for the change rather than just announcing the publication of a report, it falls under the category of general regulatory filings. FY 2023
2024-03-12 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.